Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary

Impel Pharmaceuticals (NASDAQ: IMPL) announced its participation in two investor conferences in March 2023. The 43rd Annual TD Cowen Health Care Conference will feature a fireside chat with CEO Adrian Adams on March 8 at 11:10 a.m. ET, held in Boston, MA. Following this, the 2nd Annual Needham Virtual Neuroscience Forum will take place on March 15 at 3:20 p.m. ET, also with Adams participating. Live webcasts of both events will be accessible on the company's Investor Relations webpage, with replays available for 90 days afterward. Impel is committed to developing innovative therapies for high unmet medical needs, exemplified by its FDA-approved Trudhesa nasal spray for migraine treatment.

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming investor conferences in March:

• 43rd Annual TD Cowen Health Care Conference: Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 8, 2023 at 11:10 a.m. ET in Boston, MA.
• 2nd Annual Needham Virtual Neuroscience Forum: Adrian Adams, Chairman and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 15, 2023 at 3:20 p.m. ET.

A live webcast of each event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. Replays of the presentations will be available on the website for 90 days.

About Impel Pharmaceuticals
Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers treatments that pair its proprietary POD^® technology with well-established therapeutics. In September 2021, Impel received U.S. FDA approval for its first product, Trudhesa^® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. In addition to Trudhesa, the Company continues to address patient needs via licensing and partnerships.

For additional information about Impel, please visit www.ImpelPharma.com

Contact:

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 386-366-0616
Email: mweible@elixirhealthpr.com

Investor Relations
Janhavi Mohite
Stern Investor Relations
Phone: 212-362-1200
Email: janhavi.mohite@sternir.com

FAQ

What conferences will Impel Pharmaceuticals (IMPL) participate in March 2023?

Impel Pharmaceuticals will participate in the 43rd Annual TD Cowen Health Care Conference on March 8 and the 2nd Annual Needham Virtual Neuroscience Forum on March 15, 2023.

Who will represent Impel Pharmaceuticals at the investor conferences?

Adrian Adams, the Chairman and Chief Executive Officer, will represent Impel Pharmaceuticals at both conferences.

When is the 43rd Annual TD Cowen Health Care Conference for Impel Pharmaceuticals?

The 43rd Annual TD Cowen Health Care Conference is scheduled for March 8, 2023, at 11:10 a.m. ET.

How can I watch the conferences for Impel Pharmaceuticals (IMPL)?

Live webcasts of the conferences will be available on the Impel Pharmaceuticals Investor Relations website.

What is Trudhesa, the product by Impel Pharmaceuticals (IMPL)?

Trudhesa is a nasal spray approved by the U.S. FDA for the acute treatment of migraine with or without aura in adults.